Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. Guidelines by topic
  4. Haematological Malignancies

Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms: ESMO Clinical Practice Guidelines

Published in 2015 – Ann Oncol (2015) 26 (suppl 5): v85-v99.
Authors: A. M. Vannucchi, T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. Kröger, J. Thiele and C. Buske

Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines provide the latest information on the treatment of myeloproliferative neoplasms including recommendations for achieving an accurate diagnosis, assessing prognosis and management and follow-up strategies associated with distinct subtypes.

Related items

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.